7/5/2011

A meta-analysis in the Canadian Medical Association Journal found that healthy, middle-age users of Chantix, Pfizer's smoking-cessation drug, had a 72% greater risk of heart problems requiring hospitalization compared with placebo users. Last month, the FDA said Chantix's warning label will be revised to mention increased cardiovascular risk in those with a history of heart disease. Pfizer is working with the agency "to conduct a combined analysis of clinical-trial data" that "will
help further evaluate the cardiovascular safety of Chantix," the company said.

Full Story:
Reuters

Related Summaries